Research summary ·
α-Synuclein seed amplification assay methodology and performance in Parkinson's disease, lewy body dementia, and multiple system atrophy: A meta-analysis.
Written based on 1 research study on PubMed, searched on 3 Nov 2026.
What was studied
This review looked at seed amplification assays for synucleinopathies. They test for α-synuclein in spinal fluid, skin and olfactory mucosa. The conditions were multiple system atrophy, Parkinson's disease and Lewy body dementia. The team asked how methods varied and how well tests perform. Controls were split into disease mimics and unrelated conditions. 55 studies were included.
What they found
Methods varied between studies. They differed in the assay substrate, the replicates and the positivity threshold. For spinal fluid, median sensitivity was 0.92 and specificity 0.90. For skin, they were 0.94 and 0.86. For olfactory mucosa, they were 0.69 and 0.94. Performance dropped slightly when groups were adjusted for clinical use. It stayed high.
What it means for patients
The authors say the tests performed at a high level, even after adjustment. They name next steps. These are leaner workflows and checks of performance by disease stage and co-pathologies.
Why it is not certain yet
Ranges were wide, such as 0.33-1.0 for olfactory sensitivity. Methods differed between studies. Performance by disease stage and co-pathology still needs study.
Source
α-Synuclein seed amplification assay methodology and performance in Parkinson's disease, lewy body dementia, and multiple system atrophy: A meta-analysis.
PubMed · PMID 41621636We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Lewy body dementia publications